%0 Journal Article
%T 肝细胞癌微血管侵犯的治疗进展<br>Advances in the Treatment of Microvascular Invasion in Hepatocellular Carcinoma
%A 王粟
%A 樊海宁
%J Journal of Clinical Personalized Medicine
%P 47-53
%@ 2334-3443
%D 2024
%I Hans Publishing
%R 10.12677/JCPM.2024.31008
%X 虽然肝细胞癌(hepatocellular carcinoma, HCC)采用以根治性切除手术切除为核心的多方式、多学科治疗方式，但术后5年复发率仍达到70%，肝移植术后复发率约为35%。术后肿瘤复发是影响肿瘤患者预后的重要因素，多项研究表明微血管侵犯(microvascular invasion, MVI)是HCC术后早期复发及预后不良的独立危险因素。但是MVI需要术后病理确诊的方式严重限制了其临床价值。本文将从肝细胞癌MVI治疗方案进行文献综述。<br />
Although hepatocellular carcinoma (HCC) is treated with a multimodal and multidisciplinary ap-proach centred on radical resection with surgical excision, the 5-year postoperative recurrence rate still reaches 70%, and the recurrence rate after liver transplantation is about 35%. Postoperative tumour recurrence is an important factor affecting the prognosis of tumour patients, and several studies have shown that microvascular invasion (MVI) is an independent risk factor for early post-operative recurrence and poor prognosis of HCC. However, MVI requires postoperative pathological confirmation of diagnosis, which severely limits its clinical value. In this article, we will review the literature from the therapeutic options of MVI in hepatocellular carcinoma.
%K 肝细胞癌，微血管侵犯，治疗<br>Hepatocellular Carcinoma
%K Microvascular Invasion
%K Treatment
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=80724